Suppr超能文献

阿瑞匹坦固体过饱和自纳米乳化药物递送系统(Super-SNEDDS)的体外溶解度增强评价

In Vitro Evaluation of a Solid Supersaturated Self Nanoemulsifying Drug Delivery System (Super-SNEDDS) of Aprepitant for Enhanced Solubility.

作者信息

Nazlı Hakan, Mesut Burcu, Özsoy Yıldız

机构信息

Department of Pharmaceutical Technology, Faculty of Pharmacy, Trakya University, Edirne 22030, Turkey.

Department of Pharmaceutical Technology, Faculty of Pharmacy, Istanbul University, Istanbul 34116, Turkey.

出版信息

Pharmaceuticals (Basel). 2021 Oct 27;14(11):1089. doi: 10.3390/ph14111089.

Abstract

Aprepitant (APR) belongs to Class II of the Biopharmaceutical Classification System (BCS) because of its low aqueous solubility. The objective of the current work is to develop self-nanoemulsifying drug delivery systems (SNEDDS) of APR to enhance its aqueous solubility. Preformulation studies involving screening of excipients for solubility and emulsification efficiency were carried out. Pseudo ternary phase diagrams were constructed with blends of oil (Imwitor 988), cosolvent (Transcutol P), and various surfactants (Kolliphor RH40, Kolliphor ELP, Kolliphor HS15). The prepared SNEDDS were characterized for droplet size and nanoemulsion stability after dilution. Supersaturated SNEDDS (super-SNEDDS) were prepared to increase the quantity of loaded APR into the formulations. HPMC, PVP, PVP/VA, and Soluplus were used as polymeric precipitation inhibitors (PPI). PPIs were added to the formulations at 5% and 10% by weight. The influence of the PPIs on drug precipitation was investigated. In vitro lipolysis test was carried out to simulate digestion of formulations in the gastrointestinal tract. Optimized super-SNEDDS were formulated into free-flowing granules by adsorption on the porous carriers such as Neusilin US2. In vitro dissolution studies of solid super-SNEDDS formulation revealed an increased dissolution rate of the drug due to enhanced solubility. Consequently, a formulation to improve the solubility and potentially bioavailability of the drug was developed.

摘要

阿瑞匹坦(APR)因其低水溶性而属于生物药剂学分类系统(BCS)的II类。当前工作的目的是开发阿瑞匹坦的自纳米乳化药物递送系统(SNEDDS)以提高其水溶性。开展了涉及筛选辅料的溶解性和乳化效率的处方前研究。用油性辅料(Imwitor 988)、助溶剂(Transcutol P)和各种表面活性剂(聚氧乙烯氢化蓖麻油RH40、聚氧乙烯氢化蓖麻油ELP、聚氧乙烯氢化蓖麻油HS15)的混合物构建了伪三元相图。对制备的SNEDDS进行稀释后的粒径和纳米乳液稳定性表征。制备了过饱和SNEDDS(超级SNEDDS)以增加制剂中阿瑞匹坦的载药量。羟丙甲纤维素、聚乙烯吡咯烷酮、聚乙烯吡咯烷酮/醋酸乙烯酯共聚物和尤特奇EPO用作聚合物沉淀抑制剂(PPI)。PPI按5%和10%的重量加入制剂中。研究了PPI对药物沉淀的影响。进行了体外脂解试验以模拟制剂在胃肠道中的消化情况。通过吸附在诸如Neusilin US2等多孔载体上,将优化后的超级SNEDDS制成自由流动颗粒。固体超级SNEDDS制剂的体外溶出研究表明,由于溶解度提高,药物的溶出速率增加。因此,开发了一种提高药物溶解度并可能提高生物利用度的制剂。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acf8/8621193/216e1ca2d293/pharmaceuticals-14-01089-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验